Articles

  • PharmaTutor
    31 August 2015

    ANTIBACTERIAL, ANTIOXIDANT AND CYTOTOXIC ACTIVITIES OF TREWIA NUDIFLORA

    { DOWNLOAD AS PDF }

  • 27 August 2015
    A REVIEW AND APPLICATION OF CRYOPROTECTANT: THE SCIENCE OF CRYONICS

    { DOWNLOAD AS PDF }

  • 25 August 2015
    GABAPENTIN: A NEW BROAD SPECTRUM ANTIEPILEPTIC DRUG

    { DOWNLOAD AS PDF }

    ABOUT AUTHORS:
    Firake Bhushan M.1, Pandagale Sagar J.2, Firke Sandip D.3, Palshikar Gautam S.4
    1Department of Pharmaceutical Chemistry, JSPM’s Jayawantrao Sawant College of Pharmacy and Research, Hadapsar, Pune
    2Department of Pharmaceutical Analysis, JSPM’s Jayawantrao Sawant College of Pharmacy and Research, Hadapsar, Pune
    3Department of Pharmaceutical Chemistry, SES’s R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur
    4Department of Pharmacognosy, JSPM’s Jayawantrao Sawant College of Pharmacy and Research, Hadapsar, Pune
    bmf.jscopr@gmail.com

    ABSTRACT:
    Epilepsy is one of the most serious disorders of the brain, affecting about 50 million people worldwide. Epilepsy leads to multiple interacting medical, psychological, economic and social consequences. Successful seizure control is very important in decreasing the psychosocial and economic costs of epilepsy. Yet, most therapies didn’t completely improve patients for numerous reasons. The most effective antiepileptic drugs (AEDs) include phenytoin, carbamazepine, valproic acid, phenobarbital, and primidone. Of the older AEDs, carbamazepine and valproic acid together bring a threat of hepatic toxicity and have been associated with fetal anomalies. Carbamazepine and phenytoin aggravate hypersensitivity reactions in a significant number of patients, and phenytoin is associated with chronic adverse events (AEs). Phenytoin, carbamazepine, phenobarbital, and primidone are hepatic enzyme inducers. Valproic acid, on the contrary, is a powerful hepatic inhibitor.

    The newer agents have fewer drug interactions and slight, if at all, effect on the CYP450 enzyme system and other metabolic pathways. One of these new agents was gabapentin (GBP). GBP, the new antiepileptic drug (AED) has a broad spectrum of anti-seizure effects, less adverse effects and less drug interaction. GBP has since achieved international acknowledgment, not for its antiepileptic properties, but also its effectiveness in the managing of acute and chronic pain syndromes, especially neuropathic pain. It is prescribed as an add-on medication for the treatment of patients aged >12 years with partial and secondary generalized tonic-clonic seizures and for children aged 3 to 12 years with partial seizures. It has been used for monotherapy in adults in 38 countries. Gabapentin is regarded as safe and tolerable with a promising pharmacokinetic profile and an extensive therapeutic index.

    The present article reviews the available information that dealing with the long-standing efficiency and safety of gabapentin in the treatment of patients with epilepsy.

  • 20 August 2015
    DATA INTEGRITY NON-COMPLIANCES – THE GOOD, BAD AND UGLY

    ABOUT AUTHORS
    Krishnendu Singha
    Manager – Quality Assurance
    [The author is a Quality Assurance professional of a leading MNC]
    Krish_singha2007@yahoo.co.in

  • 19 August 2015
    ADVANCEMENT IN COLOUR COSMETICS

    ABOUT AUTHOR:
    Vinay Kumar Singh
    General Manager-Technical,
    Mikasa Cosmetics Limited,
    Ahmedabad, Gujarat
    vinay.s@mikasacosmetics.com

  • 18 August 2015
    STUDY OF EFFECT OF SUPPLEMENTATION OF ZINGIBER OFFICINALE ON PHARMACOKINETIC PROFILE OF SITAGLIPTIN PHOSPHATE ON STREPTOZOTOCIN INDUCED TYPE II DM RAT MODEL

    { DOWNLOAD AS PDF }

    ABOUT AUTHORS:
    Swati R. Dhande, Aruhana R. Patil*, Lilasrao J. Kadam
    Bharati Vidyapeeth's College of Pharmacy,
    Belapur, Navi Mumbai
    *arpatil1991@gmail.com

    ABSTRACT
    Diabetes Mellitus (DM) is a metabolic endocrine disorder. It is one of the most rapidly growing diseases worldwide. Various pharmacotherapies have been practiced in the cure and management of DM. The existing conventional therapies aims at reducing hyperglycemia and achieving better glycemic control over the time, but fail to combat the other risk factors associated with the disease. The newer approaches are targeting to combat the risk factors and reduce the progression of disease. The newer approaches includes regenerational therapies, use of herbal and natural supplements, use of antioxidants and use combinations of conventional therapies with above mentioned therapies. Though these combinations have been found to be promising in the management of DM, the risk of pharmacological interactions cannot be overlooked. The present study was conducted to evaluate the pharmacokinetic interaction between DPP-IV inhibitor sitagliptin and a nutraceutical Z. officinale. STZ (Streptozotocin) and HFD (High Fat Diet) induced Type II DM rat model was used and the possible interaction was determined. The evaluation was done on validated HPTLC bioanalytical method. The present combination of sitagliptin and ginger did not affect the pharmacokinetic profile of sitagliptin.

  • 17 August 2015
    REVIEW: TINOSPORA CORDIFOLIA IN THE TREATMENT OF DEPRESSION

    { DOWNLOAD AS PDF }

  • 16 August 2015
    QUALITY BY DESIGN

    { DOWNLOAD AS PDF }

  • 11 August 2015
    A RARE CASE REPORT ON TUBEROUS SCLEROSIS

    { DOWNLOAD AS PDF }

  • 2 August 2015
    IMPURITY PROFILING AN EMERGING TREND IN PHARMACEUTICALS: A REVIEW

    { DOWNLOAD AS PDF }

Subscribe to Articles